Completed × Anemia, Aplastic × Clear all
NCT01758042 2026-03-06

BMT

Massachusetts General Hospital

Phase NA Completed
10 enrolled
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
35 enrolled 14 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT01272817 2022-11-23

Mini-allo

Scripps Health

Phase NA Completed
36 enrolled
NCT01384513 2022-11-17

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled
NCT01586455 2022-10-25

HPDSC

New York Medical College

Phase 1 Completed
43 enrolled
NCT02065154 2022-09-30

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

University of Alabama at Birmingham

Phase 2 Completed
39 enrolled 13 charts
NCT00003816 2021-08-13

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Roswell Park Cancer Institute

Phase 2/3 Completed
361 enrolled 16 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00856388 2019-11-13

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Roswell Park Cancer Institute

Phase NA Completed
62 enrolled 14 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT00993694 2017-04-17

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Vanderbilt University Medical Center

Completed
41 enrolled
NCT00683046 2016-11-22

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

University of Chicago

Phase 2 Completed
204 enrolled 7 charts
NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

Phase 2 Completed
17 enrolled 9 charts
NCT00513175 2012-11-09

Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia

University of California, San Francisco

Completed
44 enrolled
NCT00056966 2012-06-29

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Baylor College of Medicine

Phase 1/2 Completed
24 enrolled
NCT00516152 2009-01-26

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

University of California, San Francisco

Phase 2 Completed
36 enrolled